Abstracts tagged "patient-reported outcome measures"

Abstract Number: 1108 • 2019 ACR/ARP Annual Meeting
Mobile Apps in Rheumatology: Review and Analysis Using the Mobile App Rating Scale (MARS)
Johannes Knitza¹, Koray Tascilar ², Eva-Maria Messner ³, Marco Meyer ⁴, Diana Vossen ⁵, Almut Pulla ⁶, Philipp Bosch ⁷, Julia Kittler ⁸, Arnd Kleyer ¹, Philipp Sewerin ⁹, Johanna Mucke ¹⁰, Isabell Haase ¹¹, David Simon ¹² and Martin Krusche ¹³, ¹Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ²Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Bayern, Germany, ³Department for Clinical Psychology and Psychotherapy, Ulm University, Ulm, Germany, Ulm, Germany, ⁴Asklepios Klinik Altona, Rheumatologie, Klinische Immunologie, Nephrologie, Hamburg, Germany; German Society for Rheumatology (Working Group Young Rheumatology), Hamburg, Germany, ⁵Departement for Internal Medicine and Rheumatology, Rheinisches Rheumazentrum Meerbusch, St. Elisabeth-Hospital, Meerbusch, Germany; German Society for Rheumatology (Working Group Young Rheumatology), Meerbusch, Germany, ⁶Rheinisches Rheumazentrum Meerbusch, St. Elisabeth-Hospital, Meerbusch, Germany; German Society for Rheumatology (Working Group Young Rheumatology), Meerbusch, Germany, ⁷Department of Rheumatology and Immunology, Medical University Graz, Graz, Austria, Graz, Austria, ⁸Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany; German Society for Rheumatology (Working Group Young Rheumatology), Erlangen, Germany, ⁹Department of Rheumatology & Hiller Research Unit, University Hospital Düsseldorf,, Duesseldorf, Germany, ¹⁰Department and Hiller Research Unit of Rheumatology, Heinrich-Heine University Duesseldorf, Düsseldorf, Germany, ¹¹Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ¹²Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ¹³Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin, Berlin, Germany; German Society for Rheumatology (Working Group Young Rheumatology), Berlin, Germany
Background/Purpose: Mobile applications promise to facilitate the life of patients as well as physicians. In routine practice, however, rheumatology apps are largely unknown and little…
Abstract Number: 1209 • 2019 ACR/ARP Annual Meeting
Patient-reported Outcome Measures in Systemic Lupus Erythematosus: Use in Clinical Practice – Preliminary Results from the Integrate Project
Gamal Chehab¹, Jutta Richter ², Anna Kernder ¹, Chiara Tani ³, Valentina Lorenzoni ⁴, Elena Elefante ³, Ilaria Palla ⁵, Sara Cannizzo ⁶, Salvatore Pirri ⁶, Isotta Triulzi ⁵, Leopoldo Trieste ⁵, Giuseppe Turchetti ⁵, Marta Mosca ³ and Matthias Schneider ⁷, ¹Policlinic of Rheumatology and Hiller Research Unit Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany, ²Department and Hiller Research Unit of Rheumatology, Heinrich-Heine University Duesseldorf, Duesseldorf, Nordrhein-Westfalen, Germany, ³Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Italy, ⁴Institute of Management , Scuola Superiore Sant'Anna, Pisa, Italy, ⁵Institute of Management, Scuola Superiore Sant'Anna, Pisa, Italy, ⁶Institute of Management, Scuola Superiore Sant'Anna, Pisa, Toscana, Italy, ⁷Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany
Background/Purpose: Due to improved mortality and morbidity in systemic lupus erythematosus (SLE), non-clinical indicators and outcomes, especially patient-reported ones, have become increasingly important in disease…
Abstract Number: 329 • 2018 ACR/ARHP Annual Meeting
Use of Inter-Professional Collaboration to Improve Adherence to American College of Rheumatology Recommendations for Use of Disease Activity Measures
Elisheva Weinberger¹, Douglas Einstadter² and Marina Magrey¹, ¹Rheumatology, Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, ²Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH
Background/Purpose: “Treat to target” is the goal of therapy in the treatment of Rheumatoid Arthritis (RA) based on the 2015 American College of Rheumatology (ACR)…
Abstract Number: 549 • 2018 ACR/ARHP Annual Meeting
Unmet Treat-to-Target Goals with Available Targeted Immunomodulators in the Management of Rheumatoid Arthritis: Real World Evidence from the Corrona Registry
Dimitrios A. Pappas^1,2, Namita Tundia³, Ying Shan², Heather J Litman² and Joel Kremer⁴, ¹Columbia University, New York, NY, ²Corrona, LLC, Southborough, MA, ³AbbVie Inc., North Chicago, IL, ⁴Albany Medical College and the Center for Rheumatology, Albany, NY
Background/Purpose: Targeted immunomodulators (TIMs) have revolutionized the therapy of RA and made low disease activity (LDA) a realistic goal for patients. Given the multiple therapy…
Abstract Number: 892 • 2018 ACR/ARHP Annual Meeting
Establishing the Minimal Clinically Important Difference (MCID) for the Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL)
Nicolas Richard¹, Nigil Haroon², George Tomlinson³, Ismail Sari¹, Zahi Touma⁴ and Robert D Inman¹, ¹Rheumatology, Toronto Western Hospital, University of Toronto, Spondylitis Clinic, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: The Ankylosing Spondylitis Quality of Life (ASQoL) is a readable and simple to complete questionnaire relating to health-related quality of life (HRQoL) in subjects…
Abstract Number: 1387 • 2018 ACR/ARHP Annual Meeting
Fatigue in Patients with Rheumatoid Arthritis As Compared to Different Groups of Cancer Patients
Jens Gert Kuipers¹, Michael Koller², Ulrich Rueffer³, Florian Zeman², Karolina Mueller⁴ and Joachim Weis⁵, ¹Clinic for Internal Rheumatology, Red Cross Hospital Bremen, Bremen, Germany, ²Center of Clinical Studies, University Hospital Regensburg, Regensburg, Germany, ³German Fatigue Society, Cologne, Germany, ⁴Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany, ⁵University Clinic Centre Freiburg, Freiburg, Germany
Background/Purpose: Fatigue is a common symptom in patients with rheumatoid arthritis (RA) as well as patients with cancer. Fatigue considerably reduces the quality of life…
Abstract Number: 1644 • 2018 ACR/ARHP Annual Meeting
Improvement in Morning Stiffness in Subjects with Psa Is Associated with Improvements in Pain, Physical Function, and Patient Global Response to Treatment
Ana-Maria Orbai¹, Jessica Walsh², Peter Nash³, Lichen Teng⁴, Benoit Guerette⁴ and Rieke Alten⁵, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Utah School of Medicine, Salt Lake City, UT, USA, Salt Lake City, UT, ³University of Queensland, Brisbane, Australia, ⁴Celgene Corporation, Summit, NJ, ⁵Schlosspark-Klinik University Medicine, Berlin, Germany
Background/Purpose: Stiffness is an important component of inflammatory arthritis and plays a role in PsA flare. Patients with inflammatory arthritis report difficulty with activities, “slowing…
Abstract Number: 1715 • 2018 ACR/ARHP Annual Meeting
Safety and Efficacy of Lenabasum in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects
Robert F. Spiera¹, Laura K. Hummers², Lorinda Chung³, Tracy M. Frech⁴, Robyn T. Domsic⁵, Vivien Hsu⁶, Daniel E. Furst⁷, Jessica K. Gordon¹, Maureen D. Mayes⁸, Robert W. Simms⁹, Elizabeth Lee¹⁰, Scott Constantine¹⁰ and Barbara White¹⁰, ¹Hospital for Special Surgery, New York, NY, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ⁴Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁵Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁶Rheumatology, Robert Wood Johnson Medical School, New Brunswick, NJ, ⁷Pacific Arthritis Associates, Los Angeles; University of California, Los Angeles; University of Washington, Seattle; University of Florence, Italy, Los Angeles, CA, ⁸Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁹Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁰Corbus Pharmaceuticals, Inc., Norwood, MA
Background/Purpose: Lenabasum is a synthetic, non-immunosuppressive, selective cannabinoid receptor type 2 agonist that activates resolution of innate immune responses. Lenabasum had acceptable safety and tolerability,…
Abstract Number: 2480 • 2018 ACR/ARHP Annual Meeting
Patient-Reported Outcome Measures Used in Rheumatoid Arthritis Cohorts and Registries Around the World: An Environmental Scan from the Outcome Measures in Rheumatology Critical Outcomes in Longitudinal Observational Studies Working Group
Richard Zogala¹, Karla Criner², Maria A. Lopez-Olivo¹, Natalia Zamora³, Devesh Rai¹, Gregory Pratt⁴, Jude K. A. des Bordes¹, Robin Christensen⁵ and Maria Suarez-Almazor¹, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, ²Internal Medicine, Baylor College of Medicine, Houston, TX, ³Reumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁴Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ⁵Department of Rheumatology, Musculoskeletal Statistics Unit: The Parker Institute, Bispebjerg and Frederiksberg Hospital, & Department of Rheumatology, Odense University Hospital, Copenhagen, Denmark
Background/Purpose: International registries and cohorts could potentially provide long-term data on patient-centered outcomes. In recent years there has been a concerted effort to define a…
Abstract Number: 2633 • 2018 ACR/ARHP Annual Meeting
Disease Activity, Organ Damage and Patient-Reported Outcome Measures in Swedish Patients with Recent-Onset SLE
Rebecca Heijke¹, Mathilda Björk¹, Martina Frodlund¹, Laura McDonald², Evo Alemao³ and Christopher Sjöwall¹, ¹Linköping University, Linköping, Sweden, ²Bristol-Myers Squibb, Uxbridge, United Kingdom, ³Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Patient (pt)-reported outcome measures (PROMs) are important to inform shared decision-making between pts with SLE and physicians.1 Established measures of disease activity and organ…
Abstract Number: 1080 • 2017 ACR/ARHP Annual Meeting
Electronic Patient Reported Outcomes Increase Pediatric Rheumatology Clinic Operations Efficiency While Increasing Patient and Caregiver Satisfaction
Y. Ingrid Goh¹, Talia Goldberg², Nicholas Lao³ and Brian M. Feldman⁴, ¹Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³University of Western Ontario, London, ON, Canada, ⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Electronic Patient Reported Outcomes Increase Pediatric Rheumatology Clinic Operations Efficiency While Increasing Patient and Caregiver SatisfactionBackground/Purpose: Patient reported outcomes (PROs) are powerful tools that facilitate…
Abstract Number: 1081 • 2017 ACR/ARHP Annual Meeting
Improving Patient-Reported Outcomes Collection and Documentation for Patients with Rheumatoid Arthritis at Multilingual, Safety Net Hospital Rheumatology Clinic
Todd Liou¹, Omotoke Odimayomi¹, Laura Trupin², Jinoos Yazdany² and Mary Margaretten³, ¹University of California San Francisco, San Francisco, CA, ²Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, ³Medicine, University of California San Francisco, San Francisco, CA
Background/Purpose: The Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function-10a (PF10a) survey is a reliable and valid measure of function in patients with rheumatoid arthritis…
Abstract Number: 1235 • 2017 ACR/ARHP Annual Meeting
Perceived Stress and Fatigue in Systemic Lupus Erythematosus
Patricia P. Katz¹, Desiree R Azizoddin² and Meenakshi Jolly³, ¹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²Department of Medicine and Behavioral Sciences, Rush University, Chicago, IL, ³Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Fatigue is a common and often severe symptom among individuals with systemic lupus erythematosus (SLE). Yet, there is an incomplete understanding of the causes…
Abstract Number: 1476 • 2017 ACR/ARHP Annual Meeting
Effect of Treat-to-Target Tocilizumab- and Methotrexate-Based Strategies on Health-Related Quality of Life in Newly Diagnosed Rheumatoid Arthritis Patients: Results of the U-Act-Early Trial
Xavier M Teitsma¹, Johannes WG Jacobs¹, Paco MJ Welsing², Attila Pethö-Schramm³, Michelle EA Borm⁴, Jacob M. van Laar⁵, Floris PJ Lafeber⁵ and Johannes W.J. Bijlsma², ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³F. Hoffmann-La Roche, Basel, Switzerland, ⁴Beneluxlaan 2a, Roche Nederland BV, Woerden, Netherlands, ⁵Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Patient-reported outcomes are, in addition to other efficacy and safety related outcomes, important reflections of effectiveness and adverse effects of a therapy. The Outcomes…
Abstract Number: 1477 • 2017 ACR/ARHP Annual Meeting
Patient-Reported Outcomes As Independent Measures of Treatment Success with Sirukumab, an Anti-IL6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis: Post-Hoc Analysis of 2 Placebo-Controlled Phase 3 Trials
Vibeke Strand¹, Rita Ganguly², Nan Li³, Prasheen Agarwal³, Shihong Sheng³, Kaiyin Fei³, Kelly McQuarrie³ and Sharon Popik³, ¹Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ²GlaxoSmithKline, Collegeville, PA, ³Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: Sirukumab, a selective, high-affinity, human anti–IL-6 monoclonal antibody, is in development for rheumatoid arthritis (RA) and other diseases. Effects of sirukumab on RA symptoms…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].